- Advanced search
- Immuno Portal
- Malaria Portal
Ligand id: 6912
View more information in the IUPHAR Pharmacology Education Project: ibrutinib
Molecular properties generated using the CDK
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
1. Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, Grant B, Sharman JP, Coleman M, Wierda WG et al.. (2013)
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.
N. Engl. J. Med., 369 (1): 32-42. [PMID:23782158]
2. Byrd JC, Harrington B, O'Brien S, Jones JA, Schuh A, Devereux S, Chaves J, Wierda WG, Awan FT, Brown JR et al.. (2016)
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.
N. Engl. J. Med., 374 (4): 323-32. [PMID:26641137]
3. Lou Y, Owens TD, Kuglstatter A, Kondru RK, Goldstein DM. (2012)
Bruton's tyrosine kinase inhibitors: approaches to potent and selective inhibition, preclinical and clinical evaluation for inflammatory diseases and B cell malignancies.
J. Med. Chem., 55 (10): 4539-50. [PMID:22394077]
4. Pan Z, Scheerens H, Li SJ, Schultz BE, Sprengeler PA, Burrill LC, Mendonca RV, Sweeney MD, Scott KC, Grothaus PG et al.. (2007)
Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase.
ChemMedChem, 2 (1): 58-61. [PMID:17154430]